Recruiting
Evaluation of YB-101 for Safety, Tolerability, Pharmacokinetics, and Efficacy in Graves' Disease
NCT07682896
- Conditions
- Autoimmune Diseases, Endocrine System Diseases, Exophthalmos, +8 more
- Locations
-
- Site 112 Gilbert, Arizona, United States
- Site 130 Phoenix, Arizona, United States
- Site 121 La Mesa, California, United States
- Site 103 Sacramento, California, United States